GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CELLDEX THERAPEUTICS INC

Financial Performance:

• As of Q3, the company holds $650 million in cash.
• Capital position is sufficient to fund operations through 2028, extending to the initial commercial launch.
• No specific revenue, earnings, or margin metrics were disclosed, as the company is pre-launch.

Guidance and Future Outlook:

• BLA submission for Barzavolumab (CSU) is targeted for 2027 following the availability of full 52-week data.
• The Quad AI meeting in February 2027 is expected to present full 24-week efficacy and safety data.
• Atopic Dermatitis (AD) clinical data is anticipated to be released by the end of the current year.
• Additional guidance regarding the Sindut (hives) Phase 3 enrollment and data is planned for the coming months.

Business Segments and Product Lines:

• Barzavolumab (CSU): Phase III results demonstrate a complete response rate in a majority of patients, with efficacy in Omalizumab-refractory populations and a flexible dosing regimen (Q4 or Q8, maximum 7 doses/year).
• Barzavolumab (Sindut): Phase 3 trials are ongoing and enrolling well; the product aims to be the second therapy in this market with high unmet need.
• CDX-622: A novel SCF/TSLP bifunctional antibody in early development; currently conducting proof-of-mechanism studies in asthma with future interest in food allergy and other immunoinflammatory diseases.
• Commercial Infrastructure: Building a targeted medical science liaison (MSL), market analytics, brand, and payer team in anticipation of Payer Exchange in H1 2027.

Market and Competitive Landscape:

• Chronic Spontaneous Urticaria (CSU) market is under-penetrated, with only 30% of prevalent patients diagnosed and <20% of eligible patients receiving advanced therapy.
• Current therapies have complete response rates of 30-38% and high 1-year attrition rates (~50%), creating a significant opportunity for Barzavolumab.
• Barzavolumab is positioned to capture first-line patients with severe disease/angioedema (estimated >25% of first-line) and become the preferred second-line therapy.
• Pricing strategy aims for a premium value-based price, leveraging the clinical differentiation of complete response to justify cost-of-care savings for payers.

Risks and Challenges:

• Safety profile includes a history of kit-mediated events (mild to moderate); two adjudicated cases of probable anaphylaxis occurred in the Phase 3 study post-dose 1, though the placebo arm also had one adjudicated case.
• Regulatory labeling regarding the "Omalizumab-refractory" indication requires FDA negotiation.
• Phase 3 durability data (off-therapy response) will take longer to mature than Phase 2, requiring investors to wait for long-term follow-up.
• Previous pipeline programs (PN, AD) faced mixed results, though the team remains optimistic for AD pending final data.

Management Commentary and Tone:

• Tone is highly confident, describing the Phase 3 data as "best-in-disease efficacy" and "practice-changing."
• Management emphasizes the uniqueness of the safety profile (lower anaphylaxis in drug arm vs. placebo) and the robustness of the dataset.
• Leadership expresses clear strategic focus on building a disciplined, high-ROI commercial infrastructure and highlights the synergy between the current pipeline assets.

Analyst Questions and Answers:

• BLA Timing: Confirmed 2027 submission based on 52-week data; Q4 AI 2027 will present 24-week efficacy/safety.
• Safety Clarification: Addressed confusion over anaphylaxis rates, clarifying that the drug arm had zero adjudicated anaphylaxis cases compared to one in the placebo arm, and that investigator-assessed Grade 4 events are not synonymous with adjudicated anaphylaxis.
• Market Size: Projected Barzavolumab could be a $4 billion product, analogizing CSU growth to the evolution of the psoriasis market with IL-23 therapies.
• Labeling: Expects the "Omalizumab-refractory" indication to be included in the label.
• Pipeline: CDX-622 targets different pathways (SCF/TSLP) than Barzavolumab (Kit receptor), offering complementary mechanisms for future immunoinflammatory diseases.

Other Key Points:

• The CSU market is expected to follow historical trends of other autoimmune diseases where second-line therapy eventually eclipses first-line therapy once a novel biologic demonstrates superior efficacy.
• The "off-therapy prolonged response" seen in Phase 2 is a key differentiator, though Phase 3 durability data will require waiting for the full follow-up period.
• The company plans to present multiple secondary and exploratory endpoints in the coming months to support the BLA.